May 1st 2024
C. Ola Landgren, MD, PhD, discussed the FDA’s unanimous ODAC vote supporting minimal residual disease as an accelerated approval end point in multiple myeloma and the implications of this vote in the myeloma research field.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Biology, Time to Relapse Should Be Factored Into Treatment for Relapsed/Refractory Multiple Myeloma
October 26th 2017The treatment approach for patients with relapsed/refractory multiple myeloma should be tailored based on biology of the disease, frailty of the patient, and comorbidities, said Natalie S. Callander, MD, in a presentation at the NCCN 12th Annual Congress: Hematologic Malignancies in San Francisco, California.
Read More
High Response Rates Seen With VCD Induction Therapy in Myeloma
October 25th 2017According to phase II results from the DSMM XI trial published in the <em>British Journal of Haematology</em>, induction therapy with bortezomib (Velcade), cyclophosphamide, and dexamethasone demonstrated an overall response rate of 85.4% in treatment-naïve patients with multiple myeloma.
Read More
Lenalidomide Maintenance Therapy Post-ASCT Demonstrates Survival Benefit in Myeloma
October 25th 2017In patients with newly diagnosed multiple myeloma, maintenance therapy with lenalidomide (Revlimid) induced a survival benefit following autologous stem-cell transplantation, according to results from a meta-analysis published in the <em>Journal of Clinical Oncology</em>.
Read More
Orlowski on the Role of Maintenance Therapy in Multiple Myeloma
October 12th 2017Robert Z. Orlowski, MD, PhD, recently discussed 2 cases of patients with multiple myeloma, and the treatment considerations and decisions he would make when treating these patients. Orlowski, chairman, ad interim, director of myeloma, and professor of medicine, The University of Texas MD Anderson Cancer Center, discussed these cases during a <em>Targeted Oncology</em> live case-based peer perspectives dinner.
Read More
Remaining Questions With Multiple Myeloma Treatment
September 15th 2017Robert Orlowski, MD, PhD, Florence Maude Thomas Cancer Research professor and chair, ad interim, Department of Lymphoma & Myeloma at The University of Texas MD Anderson Cancer Center, discusses remaining questions with multiple myeloma treatment.
Watch
Dr. Jagannath Discusses the STORM and STOMP Trials for Patients With Multiple Myeloma
September 12th 2017Sundar Jagannath, MDDS, professor, Medicine, Hematology, and Medical Oncology, Mount Sinai Hospital, discusses the STORM and STOMP clinical trials in patients with multiple myeloma.
Watch
Multiple Durvalumab Combination Trials Placed on Hold by FDA
September 8th 2017Multiple trials in Celgene’s FUSION program, which is exploring regimens combining the PD-L1 inhibitor durvalumab (Imfinzi) with immunomodulatory and chemotherapy agents across several hematologic malignancies, have been placed on clinical holds by the FDA.
Read More
sNDA for Carfilzomib Label Update in Myeloma Accepted by FDA
August 31st 2017A supplemental new drug application seeking to add overall survival data from the phase III ENDEAVOR trial to the label for carfilzomib (Kyprolis) for use in patients with relapsed or refractory multiple myeloma has been accepted by the FDA.
Read More
Carfilzomib Shows Overall Survival Benefit Over Bortezomib in Myeloma
August 25th 2017Carfilzomib (Kyprolis) reduced the risk of death by 21% compared with bortezomib (Velcade) in patients with relapsed/refractory multiple myeloma, according to results from the phase III ENDEAVOR trial, now published in the<em> Lancet Oncology.</em>
Read More
Dr. Lonial Discusses the Importance of Partnering With a Myeloma Center
August 14th 2017Sagar Lonial, MD, professor and chair, Department of Hematology & Medical Oncology, Emory University School of Medicine, chief medical officer, Winship Cancer Institute of Emory University, discusses the importance of partnering with a myeloma center when managing multiple myeloma.
Watch
sNDAs for Carfilzomib to Treat Multiple Myeloma Submitted in Europe, US
August 11th 2017Supplemental New Drug Applications were recently submitted in the United States and Europe for carfilzomib (Kyprolis). The sNDAs were submitted based on data from 2 phase III studies showing carfilzomib improves overall survival for patients with relapsed/refractory multiple myeloma.
Read More
Survival Extended With Carfilzomib Combo in Myeloma, Final Analysis of ASPIRE Trial Shows
August 10th 2017The combination of carfilzomib (Kyprolis), lenalidomide (Revlimid), and dexamethasone reduced the risk of death by 21% compared with lenalidomide and dexamethasone alone for patients with relapsed multiple myeloma following prior treatment with 1 to 3 regimens.
Read More
CAR T-Cell Therapy for Myeloma and Other Hematologic Malignancies
August 7th 2017Sagar Lonial, MD, professor and chair, Department of Hematology & Medical Oncology, Emory University School of Medicine, chief medical officer, Winship Cancer Institute of Emory University, discusses CAR T-cell therapy for myeloma and other hematologic malignancies.
Watch